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“Of all the classical precipitants of zoster, two—leukaemia and x-rays—are at present the 
most important”, said R Edgar Hope-Simpson in 1965.1 The link between compromised 
immunity and herpes zoster has been recognised for more than half a century. Individuals 
who are severely immunocompromised due to immunosuppressive conditions or therapies 
have herpes zoster more frequently and severely than the general immunocompetent 
population. Herpes zoster incidence per 1000 person-years at risk is reported to be 43·03 in 
adults with bone-marrow or stem-cell transplants, 17·04 in adults with solid organ 
transplants, and 17·43 in adults with HIV, compared with 4·82 in the general 
population.2Complications of herpes zoster are also roughly three times higher in people 
with HIV than in an age-matched general population.3 Furthermore, severe 
immunocompromise is a contraindication to receiving live attenuated varicella zoster virus 
vaccine because of the potential risk of the vaccine virus replicating to cause disease. 
Preventing herpes zoster and its complications in individuals who are severely 
immunocompromised, therefore, remains an important public health goal. 
In The Lancet Infectious Diseases, Kathleen Mullane and colleagues4 report promising 
efficacy and safety of a γ irradiation-inactivated varicella zoster virus vaccine (vOka strain) in 
patients with solid tumour malignancies receiving chemotherapy. In the randomised, double-
blind, placebo-controlled, phase 3 trial done across 40 countries, the primary endpoint—
herpes zoster incidence—was markedly reduced in patients with solid tumour malignancies 
receiving vaccine compared with those receiving placebo (22 vs 61 cases; vaccine efficacy 
63·6%, 97·5% CI 36·4 to 79·1). These results came from 2678 patients with solid tumour 
malignancies on chemotherapy followed up for a mean of 2·45 years (SD 1·52) who each 
received at least one dose of the vaccine (the modified intention-to-treat population). The 
vaccine did not, however, reduce herpes zoster incidence in 2552 patients with 
haematological malignancies who received at least one vaccine dose (vaccine efficacy 
16·8%, 97·5% CI −17·8 to 41·3). 
The vaccine was well tolerated in patients with solid tumour malignancies receiving 
chemotherapy, with no differences between groups in frequencies of serious adverse events 
or vaccine-related serious adverse events up to 28 days after the fourth dose. Vaccine-
related adverse events, which were typically mild injection-site reactions, were, however, 
more common in those receiving the γ irradiation-inactivated vaccine than in those receiving 
placebo (36·2% vs 14·1%). A similar safety profile was seen in patients with haematological 
malignancies. 
Non-live vaccines are likely to hold the key to preventing herpes zoster in individuals who 
are immunocompromised. However, questions remain about which vaccine to use for which 
patient group. The study by Mullane and colleagues highlights the heterogeneity of vaccine 
responses between patients with different immunocompromising conditions. It also raises an 
important issue about the validity of immunogenicity endpoints in vaccine trials. Although 
individuals with haematological malignancies in this trial appeared to mount an effective 
immune response to the γ-irradiated vaccine, this response did not translate into clinical 
efficacy.4 
 
Another non-live herpes zoster vaccine (Shingrix; GlaxoSmithKline, King of Prussia, PA, 
USA) is also undergoing clinical trials in patients who are immunocompromised. Licensed to 
prevent herpes zoster and post-herpetic neuralgia in adults aged 50 years and older, this 
adjuvanted recombinant vaccine is highly efficacious in older adults who are 
immunocompetent (vaccine efficacy of around 90% in all age groups from 50 years).5 Its 
safety and immunogenicity have been established in phase 1/2 trials in recipients of 
autologous haemopoietic stem-cell transplants6 and people with HIV,3 as well as in phase 3 
trials in patients who have had renal transplantation.7 Phase 3 trial data published alongside 
the Article of Mullane and colleagues showed safety and immunogenicity of Shingrix in 
patients with haematological malignancies receiving immunosuppressive therapies.8 Early 
trial results suggest that efficacy of this vaccine against incident herpes zoster is 87% in 
patients with haematological malignancies,9 68% in individuals with autologous 
haemopoietic stem-cell transplants,10 and 68% in patients who have had a renal transplant 
(NCT01610414). The efficacy of the γ irradiation-inactivated vaccine in recipients of 
autologous haemopoietic stem-cell transplants was 64% in a phase 3 trial.11 
The duration of protection conferred by non-live vaccines in individuals who are severely 
immuno-compromised remains unclear. Despite administration of four vaccine doses each a 
month apart in the study by Mullane and colleagues, response to the γ irradiation-inactivated 
vaccine waned markedly over time (vaccine efficacy of around 80% for months 0–12 vs 44% 
beyond 1 year). Duration of immunity has not yet been reported for the attenuated 
recombinant vaccine in individuals who are immunocompromised, although vaccine efficacy 
remains higher than 88% against incident herpes zoster at 4 years in older adults who are 
immunocompetent.5 
In summary, non-live vaccines offer new hope for preventing herpes zoster and its costly 
complications in individuals who are immunocompromised. Although implementation plans 
have yet to be finalised, some countries such as the UK are likely to recommend the 
recombinant herpes zoster vaccine for patients who are immunocompromised and aged 50 
years or older in the coming months. Large studies with clinically meaningful endpoints will 
provide further insights into the relative efficacies, duration of protection, long-term safety, 
and cost-effectiveness of non-live zoster vaccines for different immunocompromised groups. 
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